Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Blood

Volumn 121, Issue 20, 2013, Pages 4175-4183

  Bolton Gillespie, Elisabeth ^a   Schemionek, Mirle ^b   Klein, Hans Ulrich ^c   Flis, Sylwia ^a   Hoser, Grazyna ^d   Lange, Thoralf ^e   Nieborowska Skorska, Margaret ^a   Maier, Jacqueline ^e   Kerstiens, Linda ^c   Koptyra, Mateusz ^a   Müller, Martin C ^f   Modi, Hardik ^g   Stoklosa, Tomasz ^h   Seferynska, Ilona ⁱ   Bhatia, Ravi ^g   Holyoake, Tessa L ^j   Koschmieder, Steffen ^b   Skorski, Tomasz ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF AACHEN MEDICAL CENTER   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁱ INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HISTONE H2AX; IMATINIB; P21 ACTIVATED KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SUBPOPULATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOID LEUKEMIA CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL; ANIMAL; CANCER STEM CELL; CELL CULTURE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELLS, CULTURED; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; GENOMIC INSTABILITY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REACTIVE OXYGEN SPECIES;

MLCS; MLOWN;

EID: 84881017449     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-466938     Document Type: Article

References (55)

1. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441-453.
2. Eiring AM, Khorashad JS, Morley K, Deininger MW. Advances in the treatment of chronic myeloid leukemia. BMC Med. 2011;9:99.
3. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1): 396-409.
4. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254-2264.
5. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003;17(10):1195-1214.
6. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3(4): 276-285.
7. Nieborowska-Skorska M, Kopinski PK, Ray R, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood. 2012; 119(18):4253-4263.
8. Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia. 2008;22(10): 1969-1972.
9. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006;108(1):319-327.
10. Khorashad JS, De Melo VA, Fiegler H, et al. Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis. Leukemia. 2008;22(9):1806-1807.
11. Bacher U, Haferlach T, Hiddemann W, Schnittger S, Kern W, Schoch C. Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet. 2005;157(1):53-61.
12. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005;106(6):2128-2137.
13. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005;23(18):4100-4109.
14. Brazma D, Grace C, Howard J, et al. Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes Cancer. 2007;46(11): 1039-1050.
15. Grossmann V, Kohlmann A, Zenger M, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011; 25(3):557-560.
16. Haferlach C, Bacher U, Schnittger S, Weiss T, Kern W, Haferlach T. Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment. Leukemia. 2010;24(3):638-640.
17. Nowak D, Ogawa S, Müschen M, et al. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations [published correction appears Blood. 2010; 115(19):4006.]. Blood. 2010;115(5):1049-1053.
18. Yin CC, Cortes J, Galbincea J, et al. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci. 2010; 101(9):2005-2010.
19. Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst. 2007;99(9):680-693.
20. Ross DM, Hughes TP, Melo JV. Do we have to kill the last CML cell? Leukemia. 2011;25(2):193-200.
21. Chu S, Holtz M, Gupta M, Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD341 cells. Blood. 2004;103(8): 3167-3174.
22. Koschmieder S, Gottgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2005;105(1):324-334.
23. Schemionek M, Elling C, Steidl U, et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood. 2010;115(16): 3185-3195.
24. Nowicki MO, Falinski R, Koptyra M, et al. BCR/ ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 2004;104(12): 3746-3753.
25. Lange T, Park B, Willis SG, Deininger MW. BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle. 2005;4(12): 1761-1766.
26. Alikian M, Gerrard G, Subramanian PG, et al. BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol. 2012;87(3):298-304.
27. Bengtsson H, Wirapati P, Speed TP. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics. 2009;25(17):2149-2156.
28. Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010;2(6):640-653.
29. Miyazaki K, Yamasaki N, Oda H, et al. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia. Blood. 2009; 113(19):4702-4710.
30. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191): 110-114.
31. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21): e198-e206.
32. Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci U S A. 1991;88(14): 6293-6297.
33. Joha S, Dauphin V, Leprêtre F, et al. Genomic characterization of Imatinib resistance in CD341 cell populations from chronic myeloid leukaemia patients. Leuk Res. 2011;35(4):448-458.
34. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene. 2009; 28(28):2545-2555.
35. Deacon SW, Beeser A, Fukui JA, et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol. 2008;15(4):322-331.
36. de Lavallade H, Finetti P, Carbuccia N, et al. A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leuk Res. 2010;34(2):254-257.
37. Frank O, Brors B, Fabarius A, et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia. 2006;20(8):1400-1407.
38. Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukemia: implications and management strategies. Cancer. 2012;118(5):1181-1191.
39. Shao L, Feng W, Lee KJ, Chen BP, Zhou D. A sensitive and quantitative polymerase chain reaction-based cell free in vitro non-homologous end joining assay for hematopoietic stem cells. PLoS ONE. 2012;7(3):e33499.
40. Zhang B, Ho YW, Huang Q, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21(4):577-592.
41. Barnes DJ, Palaiologou D, Panousopoulou E, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005; 65(19):8912-8919.
42. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657-667.
43. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107(11):4532-4539.
44. Mohrin M, Bourke E, Alexander D, et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell. 2010;7(2):174-185.
45. Machová Poláková K, Lopotová T, Klamová H, et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 2011;10:41.
46. Sattler M, Winkler T, Verma S, et al. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 1999;93(9):2928-2935.
47. Schmidt T, Kharabi Masouleh B, Loges S, et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(1) leukemia. Cancer Cell. 2011;19(6): 740-753.
48. Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1999; 1(5):253-259.
49. Li J, Li Q, Xie C, et al. Beta-actin is required for mitochondria clustering and ROS generation in TNF-induced, caspase-independent cell death. J Cell Sci. 2004;117(Pt 20):4673-4680.
50. Sorel N, Bonnet ML, Guillier M, Guilhot F, Brizard A, Turhan AG. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun. 2004; 323(3):728-730.
51. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107(2): 76-94.
52. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103(8):2794-2799.
53. Sherbenou DW, Hantschel O, Turaga L, et al. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 2008;22(6):1184-1190.
54. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20): 5565-5572.
55. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118(13): 3657-3660.